In advanced atherosclerotic Apoe-/- mouse models, does ABT-263 senolytic treatment support a narrow warning that senescent-cell clearance can reduce smooth-muscle-associated plaque features while simultaneously increasing endothelial-to-mesenchymal transition and mortality risk, and should this signal be framed as a therapeutic-window concern rather than as evidence that senolytics are broadly harmful or broadly beneficial?

Citation Support

No citation support attached yet.